| Basics |
Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.
|
| IPO Date: |
October 1, 2002 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$370.07M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.14 | 3.90%
|
| Avg Daily Range (30 D): |
$0.24 | 4.27%
|
| Avg Daily Range (90 D): |
$0.19 | 3.81%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.33M |
| Avg Daily Volume (30 D): |
.37M |
| Avg Daily Volume (90 D): |
.3M |
| Trade Size |
| Avg Trade Size (Sh.): |
240 |
| Avg Trade Size (Sh.) (30 D): |
143 |
| Avg Trade Size (Sh.) (90 D): |
153 |
| Institutional Trades |
| Total Inst.Trades: |
52 |
| Avg Inst. Trade: |
$1.99M |
| Avg Inst. Trade (30 D): |
$2.97M |
| Avg Inst. Trade (90 D): |
$2.97M |
| Avg Inst. Trade Volume: |
.4M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.81M |
| Avg Closing Trade (30 D): |
$1.87M |
| Avg Closing Trade (90 D): |
$1.87M |
| Avg Closing Volume: |
908.96K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-.59
|
$-.13
|
$-.12
|
|
Diluted EPS
|
$-.59
|
$-.13
|
$-.12
|
|
Revenue
|
$ M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -37.3M
|
$ -8.18M
|
$ -7.52M
|
|
Operating Income / Loss
|
$ -29.15M
|
$ -4.2M
|
$ -4.63M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ M
|
$ M
|
$ 7.69M
|
|
PE Ratio
|
|
|
|
|
|
|
